Overview

Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia

Status:
Terminated
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the role of time of dosing on the lipid-lowering effects of lapaquistat acetate, once daily (QD) or twice daily (BID), in subjects with hypercholesterolemia.
Phase:
Phase 2
Details
Lead Sponsor:
Takeda